X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/04/25/2869233/0/en/Junshi-Biosciences-Announces-NDA-Acceptance-in-Hong-Kong-for-Toripalimab.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761240
https://www.globenewswire.com/news-release/2024/04/07/2858828/0/en/Junshi-Biosciences-Announces-Approval-of-the-sNDA-for-Toripalimab-for-the-1st-Line-Treatment-of-Renal-Cancer.html
https://www.globenewswire.com//news-release/2024/02/02/2822598/0/en/Junshi-Biosciences-Announces-Toripalimab-s-NDA-Accepted-by-the-Singapore-Health-Sciences-Authority.html
https://www.globenewswire.com//news-release/2024/01/18/2811217/0/en/Junshi-Biosciences-Announces-JAMA-Publication-of-Results-from-NEOTORCH-a-Randomized-Phase-3-Trial-of-Perioperative-Toripalimab-plus-Chemotherapy-for-Patients-with-Resectable-Non-Sm.html
https://www.globenewswire.com//news-release/2024/01/10/2806779/0/en/Junshi-Biosciences-Announces-Publication-of-Results-from-TORCHLIGHT-a-Randomized-Phase-3-Trial-of-Toripalimab-for-the-Treatment-of-Metastatic-or-Recurrent-Triple-negative-Breast-Ca.html
https://www.prnewswire.com/news-releases/inovio-and-coherus-announce-clinical-collaboration-to-advance-development-of-ino-3112-in-combination-with-loqtorzi-toripalimab-tpzi-302025891.html
https://www.globenewswire.com//news-release/2024/01/02/2802648/0/en/Junshi-Biosciences-Announces-Approval-of-the-Supplemental-New-Drug-Application-for-Toripalimab-as-Perioperative-Treatment-for-Resectable-NSCLC-Patients.html
https://www.globenewswire.com//news-release/2023/12/11/2793856/33333/en/Coherus-Announces-Updated-NCCN-Clinical-Practice-Guidelines-Positioning-LOQTORZI-toripalimab-tpzi-as-Preferred-Category-1-Regimen-for-First-Line-Treatment-of-Cancer-of-the-Nasophar.html
https://www.globenewswire.com//news-release/2023/12/02/2789608/0/en/Junshi-Biosciences-Announces-New-Chemical-Entity-Application-for-Toripalimab-Accepted-by-Australia-s-TGA.html
https://www.globenewswire.com//news-release/2023/11/28/2787206/33333/en/Coherus-and-Junshi-Biosciences-Announce-Publication-of-Positive-Final-Overall-Survival-Results-of-JUPITER-02-a-Phase-3-Trial-Evaluating-LOQTORZI-toripalimab-tpzi-as-Treatment-for-N.html
https://www.globenewswire.com//news-release/2023/10/27/2768663/33333/en/Coherus-and-Junshi-Biosciences-Announce-FDA-Approval-of-LOQTORZI-toripalimab-tpzi-in-All-Lines-of-Treatment-for-Recurrent-or-Metastatic-Nasopharyngeal-Carcinoma-NPC.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761240
https://www.globenewswire.com/news-release/2023/07/20/2707845/0/en/Junshi-Biosciences-Announces-Acceptance-of-the-Supplemental-New-Drug-Application-for-Toripalimab-as-the-First-line-Treatment-of-Extensive-stage-Small-Cell-Lung-Cancer.html
https://www.onclive.com/view/china-s-nmpa-accepts-snda-for-frontline-toripalimab-plus-axitinib-in-metastatic-rcc
https://www.globenewswire.com/news-release/2023/07/12/2703193/0/en/Junshi-Biosciences-Announces-Acceptance-of-the-Supplemental-New-Drug-Application-for-Toripalimab.html
https://www.globenewswire.com/news-release/2023/06/29/2696711/0/en/Junshi-Biosciences-Announces-Initiation-of-Phase-3-Study-of-Tifcemalimab-plus-Toripalimab-for-Treatment-of-Limited-stage-Small-Cell-Lung-Cancer.html
https://www.globenewswire.com/news-release/2023/06/05/2682408/33333/en/Coherus-Announces-Positive-Final-Overall-Survival-Results-of-JUPITER-02-Phase-3-Trial-Evaluating-Toripalimab-in-Nasopharyngeal-Carcinoma.html
https://endpts.com/fda-inspection-of-china-based-site-making-coherus-potential-new-cancer-drug-ends-with-three-observations/
https://www.clinicaltrialsarena.com/news/harbour-results-hcc-combo-therapy/
https://www.prnewswire.com/news-releases/harbour-biomed-reports-results-of-phase-ib-clinical-trial-of-porustobart-in-combination-of-toripalimab-in-patients-with-hepatocellular-carcinoma-at-asco-2023-301836298.html
https://www.prnewswire.com/news-releases/i-mab-announces-encouraging-phase-1b2-study-results-of-patients-with-advanced-nsclc-receiving-uliledlimab-and-toripalimab-combination-therapy-at-asco-2023-301834501.html
https://www.globenewswire.com/news-release/2023/05/23/2673923/0/en/Junshi-Biosciences-Announces-Acceptance-of-the-Supplemental-NDA-for-Toripalimab-in-Combination-with-Chemotherapy-for-Advanced-Triple-negative-Breast-Cancer.html
https://www.globenewswire.com/news-release/2023/05/07/2662942/0/en/Junshi-Biosciences-Announces-Collaboration-with-Dr-Reddy-s-to-Develop-and-Commercialize-Toripalimab-in-21-Countries.html
https://www.globenewswire.com/news-release/2023/04/27/2656314/33333/en/Coherus-and-Junshi-Biosciences-Announce-Toripalimab-Studies-to-be-Presented-at-the-2023-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html
https://www.globenewswire.com/news-release/2023/04/27/2655956/0/en/Junshi-Biosciences-Announces-Primary-Endpoint-Met-in-RENOTORCH-Study-of-Toripalimab-for-1st-line-Treatment-of-Advanced-Renal-Cell-Carcinoma.html
https://www.globenewswire.com/news-release/2023/04/20/2651527/0/en/Junshi-Biosciences-Announces-Toripalimab-plus-Chemotherapy-Significantly-Improved-Event-free-Survival-EFS-versus-Chemotherapy-as-Perioperative-Treatment-for-Resectable-Stage-III-No.html
https://www.globenewswire.com/news-release/2023/04/12/2645031/0/en/Junshi-Biosciences-Announces-Acceptance-of-the-Supplemental-New-Drug-Application-for-Toripalimab-as-Perioperative-Treatment-for-Operable-NSCLC-Patients.html
https://www.globenewswire.com/news-release/2023/02/21/2611703/0/en/Junshi-Biosciences-Announces-Toripalimab-in-Combination-with-Chemotherapy-for-Treatment-of-Advanced-Triple-negative-Breast-Cancer-Met-Primary-Endpoint-in-Phase-3-Clinical-Study.html
https://www.globenewswire.com/news-release/2023/02/15/2608867/0/en/Junshi-Biosciences-and-Coherus-Announce-Positive-Final-Overall-Survival-Results-of-JUPITER-02-a-Phase-3-Clinical-Trial-Evaluating-Toripalimab-as-Treatment-for-Recurrent-or-Metastat.html
https://www.globenewswire.com/news-release/2023/01/18/2590586/0/en/Junshi-Biosciences-Announces-Toripalimab-as-Perioperative-Treatment-for-Operable-NSCLC-Patients-Met-Primary-Endpoint-in-Phase-3-Clinical-Study.html
https://www.hikma.com/newsroom/article-i6076-hikma-and-junshi-biosciences-sign-exclusive-licensing-agreement-for-cancer-treatment-drug-toripalimab-for-the-middle-east-and-north-africa-region/
https://www.globenewswire.com//news-release/2022/12/26/2579424/0/en/Junshi-Biosciences-and-Hikma-Sign-Exclusive-Licensing-Agreement-for-Cancer-Treatment-Drug-Toripalimab-for-the-Middle-East-and-North-Africa-Region.html
https://www.globenewswire.com//news-release/2022/12/24/2579337/33333/en/Coherus-and-Junshi-Biosciences-Share-Update-on-the-FDA-Review-of-the-Biologics-License-Application-BLA-for-Toripalimab-as-Treatment-for-Recurrent-or-Metastatic-Nasopharyngeal-Carci.html
https://www.globenewswire.com/news-release/2022/11/15/2555612/0/en/Junshi-Biosciences-Announces-Submission-of-a-Marketing-Authorization-Application-to-the-European-Medicines-Agency-for-Toripalimab.html
https://www.globenewswire.com/news-release/2022/09/20/2519421/0/en/Junshi-Biosciences-Receives-NMPA-Approval-of-sNDA-for-Toripalimab-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Advanced-Non-squamous-Non-Small-Cell-Lung-Cancer.html
https://www.globenewswire.com/news-release/2022/07/21/2483486/0/en/Junshi-Biosciences-Receives-Orphan-Medicinal-Product-Designation-from-the-European-Committee-for-Toripalimab-in-Treatment-of-Nasopharyngeal-Carcinoma.html
https://endpts.com/two-months-after-crl-fda-accepts-coherus-junshis-resubmission-for-pd-1-studied-in-china/
https://www.globenewswire.com/news-release/2022/06/07/2457248/0/en/Junshi-Biosciences-Highlights-Pipeline-Advances-in-Immuno-Oncology-Through-Nearly-40-Data-Presentations-of-Icatolimab-and-Toripalimab-at-ASCO-2022.html
https://www.fiercebiotech.com/clinical-data/asco-i-mabs-antibody-combo-performs-best-first-line-treatment-patient-pool-may-be
https://www.globenewswire.com/news-release/2022/05/16/2444016/0/en/Junshi-Biosciences-Receives-NMPA-Approval-of-sNDA-for-Toripalimab-in-Combination-with-Paclitaxel-and-Cisplatin-in-First-Line-Treatment-of-Advanced-or-Distant-Metastatic-Esophageal-.html
https://www.globenewswire.com/news-release/2022/04/09/2419568/0/en/Junshi-Biosciences-and-Coherus-Present-Results-of-Phase-3-Study-of-Toripalimab-in-First-Line-Treatment-of-Recurrent-or-Metastatic-Nasopharyngeal-Carcinoma-at-2022-AACR-Annual-Meeti.html
https://www.fiercepharma.com/pharma/lilly-innovent-hit-fda-rebuff-another-china-made-pd-1-cancer-drug-faces-possible-delay
https://endpts.com/with-all-eyes-on-chinese-only-oncology-data-coherus-and-junshi-uncork-win-for-pd-1-drug-in-esophageal-cancer/
https://www.globenewswire.com/news-release/2022/03/04/2397129/33333/en/Coherus-and-Junshi-Biosciences-Announce-Positive-Results-from-Phase-3-Esophageal-Cancer-Study-of-Toripalimab-Published-in-Cancer-Cell.html
https://www.globenewswire.com/news-release/2022/02/04/2379077/0/en/HUTCHMED-Initiates-Phase-Ib-II-Study-of-HMPL-453-in-Combination-with-Chemotherapy-or-Toripalimab-for-Advanced-Solid-Tumors-in-China.html
https://www.prnewswire.com/news-releases/harbour-biomed-announces-dosing-of-first-patient-in-combination-therapy-phase-ibiia-trial-of-next-generation-anti-ctla-4-antibody-301466325.html
https://www.prnewswire.com/news-releases/i-mab-announces-first-patient-dosed-in-china-phase-2-combination-trial-of-lemzoparlimab-with-toripalimab-in-patients-with-advanced-solid-tumors-301462472.html
https://www.streetinsider.com/Corporate+News/Coherus+BioSciences+%28CHRS%29%2C+Junshi+Biosciences+Announce+Positive+Interim+OS+Results+of+CHOICE-01%2C+a+Phase+3+Clinical+Trial+Evaluating+Toripalimab+in+Combination+with+Chemotherapy+as+First-Line+Treatme/19340823.html
Market Place
Share 
